CGA
GDRX icon

Crescent Grove Advisors’s GoodRx Holdings GDRX Stock Holding History

Crescent Grove Advisors’s Portfolio GDRX Stock Details GDRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-44,085
Closed -$1.72M – 263
2021
Q1 		$1.72M Buy
+44,085
New +$1.98M 0.2% 62

Other funds holding GDRX

FPM
Francisco Partners Management San Francisco, California $292M AUM 34.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SLG
Silver Lake Group Menlo Park, California $3.68B AUM 7.22% 1-Year Est. Return
AM
Atreides Management Boston, Massachusetts $5B AUM 78.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Tiger Global Management
Tiger Global Management New York $22.8B AUM 30.07% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

Crescent Grove Advisors's GDRX Position: Q2 2021 in Review

Crescent Grove Advisors sold out of GoodRx Holdings (GDRX) in Q2 2021, closing a stake of 44,085 shares — an estimated $1.72M sold.

Crescent Grove Advisors first reported a position in GDRX in Q1 2021 and held it in 1 quarter. The position peaked at $1.72M in Q1 2021. 199 funds tracked by Wall St. Rank hold GDRX as of Q2 2021.

  • Crescent Grove Advisors reported no remaining GoodRx Holdings position as of Q2 2021 after selling out during the quarter.
  • Crescent Grove Advisors sold 44,085 GoodRx Holdings shares in Q2 2021, an estimated $1.72M.
  • Crescent Grove Advisors first reported a position in GoodRx Holdings in Q1 2021 and held it in 1 quarter.
  • Crescent Grove Advisors's GoodRx Holdings position peaked at $1.72M in Q1 2021.
  • 199 funds tracked by Wall St. Rank held GoodRx Holdings as of Q2 2021.

Based on Crescent Grove Advisors's 13F filing for Q2 2021, filed 26 Jul 2021.